Phase I/II, international, multicentre, open-label, non-randomised, non-comparative, study evaluating the safety, tolerability and clinical activity of intravenously administered S64315, a selective Mcl-1 inhibitor, in combination with azacitidine in patients with acute myeloid leukaemia (AML).

  • Wei, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

Effective start/end date6/10/2031/12/25


  • Malignant Haematology
  • Acute Myeloid Leukaemia (AML)
  • Clinical trial